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FIBRINOLYSIS 
AND 
OCCLUSIVE VASCULAR DISEASE 
By JOHN D. CASH, B.Sc., M.B .. Ch.B. 
Based on a Dissertation read before the Royal Medical 
Society on Friday. 20th January, 1961. 
The magnitude of the problem of occlusive vascular disease needs no 
introduction ; we should therefore be acquaint with any new therapeutic 
developments, particularly if these have reached the stage of clinical trials. 
I apologise for any bias and simplification in this article. The purpose 
of the original Dissertation was to arouse curiosity ; this article attempts to 
do no more. 
The System 
The end-product of the complicated clotting mechanism is a fibrin clot. 
Fibrinolysis appears to he an equally complicated mechanism, the end-product 
of which is an enzvme, Plasmin. which can lyse the fibrin clot. Less detail 
is known of the various stages in Fibrinolysis t h a n is known of the clotting 
mechanism. Astrup ( 19:;6), however, has produced a rough scheme which 
represents current thought fairly well. I lis scheme (Fig. 1) is based on the 
work of Christicnsen & McLeod ( 194:;). 
Space does not permit discussion of known details in the fibrinolytic process. 
Suffice to say that circulating in the blood of all mammals so far studied is 
the precursor of the enzyme, Plasminogen. In the presence of an activator, 
which in turn is the end-product of a complicated process. Plasminogen is 
converted to Plasmin. the active fibrinolytic cnzvmc. 
Inhibition of this mechanism appears to occur: So far the inhibitors appear 
to attack specifically at two sites. There arc specific inhibitors of Plasmin and 
of Plasmin activators. One circulating Plasmin inhibitor is known to be an 
a-globulin. Synthetic inhibitors have been produced. the most recent being 
D-amino caproic acid. 
Physiology 
Fearnley (1953, 19:;:;), pioneered the concept of a basal level of spontaneous 
fibrinolysis in normal people. I Hewas able to show a diurnal \'ariation. and a 
measurably higher level of activity in venous blood, particularly in that from 
the muscles. Buckcll and Elliot ( 1959) using different assay methods have
confirmed this, and agree with Mullerzt ( 1956) that the cause of the raised 
activity in venous blood was a raised level of ac t iva to r Sherry ( 1 9 6 0 has also 
confirmed a raised level of acti\'ator follo\\'ing periods of fear. parenteral adren-
aline, anoxia and after i n t r a v e n o u s acetyl choline. 
The mechanisms behind the release o f Plasminogen activator arc still for the 
most part obscure. Two significant observations, however, deserve mention. 
Albrechtscn (1957) has shown that ecrtaiu organs store a high concentration 
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of activator; the uterus. prostate, adrenal gland, thyroid. lungs and ovaries a r e
such organs. The kidneys, all muscle. testes a n d spleen have very littlc. while
the l iver has none. It is possible that those sources of activatorlisted above may 
be used to raise the level of circulating activator.
Many \\'orkcrs have found a high level of fibrinolytic activity in venous
blood draining mnsclcs, despite Albrechtscn's finding of a low yield of 
activator from muscle tissue. Kwaan & McFadyean ( 1957. 1958) in some bril-
liant experiments on this problem concluded that there exists in the walls of 
arteries. veins and of some capillaries, cholinergie effector mechanisms which 
can react locally and reflexly to release Plasminogen activator. They have
very tentatively suggested that constriction of the vasa vasorum producing 
relative ischaemia may trigger off this mechanism. Confirmation of these 
observations is urgcn tly required. 
PROACTIVATORS 
LYSOKINASES PLASMINOGEN 
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PLASMIN 
l l 
Split Products 
FIG. I. 
Pathology 
Thus we sec so far that Fibrinolysis is a complicated yet delicately con-
trolled mechanism. It is now ncccssarv to look for a n y disturbance in the 
mechanism in association with occlusive vascular disease.· 
O v e r 100 years ago Rokitansky postulated that arteriosclerosis \\'as the result 
of organisation of mural fibrin thrombi. Duguid ( 1946, 1948) has recently 
revived this hypothesis as giving a part explanation for the origin of arter-
iosclerosis. Duguid's work has been confirmed by many other \\'orkers. but he 
has shown great restraint in explaining why focal deposits of fibrin occur. Mole 
( 1948) and Astrup ( 1956) have concluded that the cause is an upset in the 
fibrinolytic mechanism. Gill man ( 1958) believes that a decreased level of 
fibrinolysis plays at least some part in thrombosis. 
W o r k has only just begun in measuring the fibrinolytic activity of circul-
a t i ng blood in patients with occlusive vascular disease. There is as yet no con-
vincing evidence of reduced fibrinolvsis after mvocardial infarction. but Ncstcl 
( 1959) has shown convincingly a 2/3 reduction in fibrinolytic activity in 
patients suffering from intermittent claudication. 
The work of Kwaan & McFadyean ( 19:;7) and Buckell & Elliott ( 1959) 
has shown that fats, specifically saturatcd fatty acids, inhibit fibrinolysis. It 
is perhaps all to easy and fashionable to relate the association of fats with 
occlusive vascular disease through fibrinolysis. M e a s u r e m e n t s of t h e fibrinolytic 
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DFWLYLW\ in diabetics on simple UHGXFLQJ GLHWV arc urgently required. In WKem. 
BHckHtt & al. ( 1960) obserYHG an incidence 20  higher than expected of 
RFFOXVLYH YDVFXODU catastrophes and SoutKZRod & al.       had SUHYLRXVO\
VKRZQ a profound lipaemia at such times. and that the I D W V were saturated. 
The HYLGHQFHsupporting the hypothesis that a disturbance of the fibrinolytic 
V \ V W H P plays D Q LPSRU WDQW role in the pathology of occlusiYH YDVFXODU disease 
is still fragmentary and FRQWURYHUVLDO NeYHUWKHOess armed with this HYLGHQFH
$PHULFDQ workers hDYH procecclccl into the exciting ILHOG of therapeutics. 
Therapeutics 
The possibility of unblocking blood YHVVHOV using fibrinolytic techniques is 
an exciting one. It is pcrhaps necessary to set apart atherosclerosis in ZKLFK
epithelization has taken place a.s compared with thc more sudden proccss of 
thrombosis or embolism. The HYLGHQFH suggesting that fibrinolytic thcrapy is 
usHful in atherosclerosis is slight and the more intcrcstillg rcsults KDYH FRPH
from treatment of thrombosis and embolism. 
At the momcnt the only HIIHFWLYHmethod LQYROYHV thc usc of human Plasmin 
intrDYenously. An American company now produces a preparation kQown as 
"' l'hrombolysin." Local infusions are necessary to bc really HIIHFWLYH as the 
circulating Plasmin inhibitors soon nullify a raised systemic fibrinolysis. 
Ruegesegger & al. ( 1960) KDYH obtained some important rcsults from radio-
graphic studies, in the dog, of occluded coronary YHVVHOV infuscd with 
"Thrombolysin.'' Their work merits close study. Frieman & al. (196) KDYH
also JLYHQ successful local infusions in dogs' pcriphcral YHVVHOV
The amount of work performed on patients is still YHU\ limitcd. The problem 
of assessing the results is particularly difficult in such fields as coronary 
thrombosis and cerebral thrombosis. NcYHrtheless, Richter & al. ( 1960) and 
Boucck & al. (1960) KDYH both reported promising results. The latter KDYH
successfully pcrfused the coronary YHVVHOV with "Thrombolysin." 
The treatment of peripheral thromboembolic disease has LQYROYHG more 
straightforward techniques and thc results therefore D U H of more GHILQLWH
significance. Anylan & al. ( 1960) and in particular Clifton ( 1960) KDYH pro-
duced some most encouraging results, from patients \\'ith femoral embolism 
and femoral thrombosis. 
The possibility of SUHYHQWLQJ occlusLYH YDscular disease becomes YHU\
real, particularly when a patient has been enabled to VXUYLYH a first acute 
attack. Since the limitations of long-term anticoagulant therapy arc daily more 
apparent, it must be considered whether a raised OHYHO of spontaneous fibrin-
olysis would not be a safer and more HIIHFWLYH prophylaxis. Certainly, at least, 
Fricman & al. ( 1960) ZHUH unable to produce artificial thrombi in thcir dogs, 
once these had been thoroughly "thrombolysed." 
,QWUDYHnous "Thrombolysin" for the rest of onc's life is REYLRXVO\ incon-
FHLYDEOH but attempts KDYH been made to find compounds which \\'hen taken 
orally will produce a raised OHYHO of spontaneous fibrinolysis. 
Finding a powerful hypolipaemic agent is an REYLRXV start in the VROYLQJ of 
this problem. Constantintidcs & al. ( 1960) KDYH reported that a snlphatcd 
polymannuronidc, " Paritol C" is a powerful hypolipaemic agent with no 
side effects. One oral dose is effHctiYe for 24 hours. FearnlHy ( 1960) and 
Singh & al. ( 1960) have produced some remarkable improvements in patients 
\\'ith intermittent claudication by giving them oral sulphonylurcas, Tolbut-
amide and Chlorpropamide. Fearnley has demonstrated a raised leve l of 
spontaneous fibrinolysis in patients taking these drugs. 
These advances in the study of Fibrinolysis promise an important break-
through in the management of occlusi\'c vascular disease. The foregoing 
FIBRINOLYSIS 
has been a brief, biased account; lest we become wildly enthusiastic it should 
be pointed out that no" double blind·· trials have yetbeen reported. There is 
a great need for more effective fibrinolytic agents and for careful. critically-
reported trials. Despite the many problems, the clinical and anatomical 
restitution of occluclcd vessels and prophylactic measures against such catas-
trophes by medical means, is an exciting goal. 
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